Drugs / Erythropoietin human recombinant
Erythropoietin human recombinant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01010802 | Aug 2008 → May 2009 | Parkinson disease | International Center for Neurological Restoration, Cuba | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Erythropoietin human recombinant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01010802 ↗ |
| Known as | EPOrh | “Erythropoietin human recombinant (EPOrh)” NCT01010802 ↗ |
| Known as | ior-EPOCIM | “Recombinant human erythropoietin produced in Cuba (ior-EPOCIM) is registered and approved for use in humans in Cuba and in a number of other countries.” PMID 22334107 ↗ Jan 2012 |
| Known as | rhEPO | “The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO.” PMID 29862060 ↗ May 2018 |
| Route | Subcutaneous | “The ior-EPOCIM was administered subcutaneously in a once-weekly dose (60 IU/kg body weight) for five weeks.” PMID 22334107 ↗ Jan 2012 |